

## Routine Schedule

Age*	Vaccine	1st Dose		2nd Dose	3rd Initial Dose
6 months–4 years	Pfizer–Infant/Toddler	1st Dose	3-8 weeks <sup>^</sup>	2nd Dose	≥8 weeks → <b>3rd Initial Dose Pfizer Bivalent<sup>β</sup></b>
6 months–5 years	Moderna–Infant/Toddler	1st Dose	4-8 weeks <sup>^</sup>	2nd Dose	<b>Bivalent Booster<sup>†</sup></b>  <b>Moderna:</b> <span style="color: #800080;">●</span> 6 months–5 years <span style="color: #000080;">●</span> 6+ years  <b>Pfizer:</b> <span style="color: #FF8C00;">●</span> 5-11 years <span style="color: #4B4B4B;">●</span> 12+ years  (For people who previously received a monovalent booster dose(s), the bivalent booster is administered at least 2 months after the last monovalent booster dose.)
5–11 years	Pfizer–Pediatric	1st Dose	3-8 weeks <sup>^</sup>	2nd Dose	
6–11 years	Moderna–Pediatric	1st Dose	4-8 weeks <sup>^</sup>	2nd Dose	
12+ years	Moderna–Adol/Adult	1st Dose	4-8 weeks <sup>^</sup>	2nd Dose	
12+ years	Pfizer/Adol/Adult	1st Dose	3-8 weeks <sup>^</sup>	2nd Dose	
12+ years	Novavax	1st Dose	3-8 weeks <sup>^</sup>	2nd Dose	
18+ years	Janssen (J&J) Pfizer/Moderna/Novavax preferred <sup>***</sup>	1st Dose			

\* See schedules for children in transition from a younger to older age group.

\*\* Although use of mRNA COVID-19 and Novavax vaccines is preferred, the Janssen vaccine may be offered in [some situations](#).

† For people who have not received any booster doses and are unable or unwilling to receive bivalent booster vaccine, the [monovalent Novavax booster may be administered as a single booster dose](#) at least 6 months after completion of the primary series to people 18 years and older.

<sup>^</sup> An [8-week interval](#) may be preferable for some people, especially for males 12-39 years.

<sup>β</sup> Children who have already received 3 monovalent doses are not eligible for the Pfizer bivalent vaccine at this time.

View [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) for details. Schedule is subject to change.

# COVID-19 Vaccine Timing

## Schedule if Moderately or Severely Immunocompromised

Age*	Vaccine	1st Dose		2nd Dose		3rd Dose	
6 months–4 years	Pfizer– Infant/Toddler	1st Dose	3 weeks	2nd Dose	≥8 weeks	3rd Initial Dose ● Pfizer Bivalent <sup>β</sup>	
6 months–5 years	Moderna– Infant/Toddler	1st Dose	4 weeks	2nd Dose	≥4 weeks	3rd Dose	
5–11 years	Pfizer– Pediatric	1st Dose	3 weeks	2nd Dose	≥4 weeks	3rd Dose	
6–11 years	Moderna– Pediatric	1st Dose	4 weeks	2nd Dose	≥4 weeks	3rd Dose	
12+ years	Moderna– Adol/Adult	1st Dose	4 weeks	2nd Dose	≥4 weeks	3rd Dose	
12+ years	Pfizer/ Adol/Adult	1st Dose	3 weeks	2nd Dose	≥4 weeks	3rd Dose	
12+ years	Novavax	1st Dose	3 weeks	2nd Dose			
18+ years	Janssen (J&J) Pfizer/Moderna/ Novavax preferred**	1st Dose	4 weeks	2nd Dose of Moderna/Pfizer			

**Bivalent Booster<sup>†</sup>**

**Moderna:**

- 6 mos–5 yrs
- 6+ years

**Pfizer:**

- 5–11 years
- 12+ years

(For people who previously received a monovalent booster dose(s), the bivalent booster is administered at least 2 months after the last monovalent booster dose.)

\* See schedules for children in transition from a younger to older age group.

\*\* Although use of mRNA COVID-19 and Novavax vaccines is preferred, the Janssen vaccine may be offered in [some situations](#).

† For people who have not received any booster doses and are unable or unwilling to receive bivalent booster vaccine, the [monovalent Novavax booster may be administered as a single booster dose](#) at least 6 months after completion of the primary series to people 18 years and older.

β Children who have already received 3 monovalent doses are not eligible for the Pfizer bivalent vaccine at this time.

View [Interim Clinical Considerations for Use of COVID-19 Vaccines](#) for details. Schedule is subject to change.